Form 4: Adicet Bio Director Andrew Sinclair Reports Stock Option Adjustments

Andrew Sinclair, a director at Adicet Bio, reported adjustments to stock options due to the rescission of a prior repricing, reverting options to their original exercise prices.

Summary

• On August 21, 2024, Adicet Bio director Andrew Sinclair reported changes in beneficial ownership related to stock options.
• The Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors.
• Affected stock options have been reverted to their original exercise price as established at the time of the grant.
• The transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
• Sinclair's report details multiple stock option adjustments with varying exercise prices and expiration dates.
• Some options were disposed of (D) and others were acquired (A) as a result of the repricing rescission.
• The shares subject to some of these options are fully vested and exercisable as of the date of the report.

Sentiment

Score: 6

Explanation: The document describes routine stock option adjustments. There is nothing inherently positive or negative, but the rescission of the repricing could be viewed as a slight positive.

Positives

• The rescission of the stock option repricing could be seen as a positive step towards aligning director compensation with long-term shareholder value.
• The transactions are exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, indicating compliance with regulations.

Industry Context

Changes to director compensation, such as stock option repricing and subsequent rescissions, are common in the biotech industry and are often scrutinized by investors for their impact on alignment with shareholder interests.

Comparison to Industry Standards

• Stock option plans for directors are a standard component of compensation packages in publicly traded biotech companies like Adicet Bio.
• Repricing of stock options, while not uncommon, can draw scrutiny if it appears to disproportionately benefit executives or directors at the expense of shareholders.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also used stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may be impacted by changes in director compensation, as it can affect alignment of interests.
• Employees are not directly impacted by this change, as it pertains to non-employee directors.

Key Dates